The ABCs of managing systolic heart failure: Past, present, and future

Cleve Clin J Med. 2016 Oct;83(10):753-765. doi: 10.3949/ccjm.83a.16006.

Abstract

Heart failure management is complex and constantly evolving. The American College of Cardiology and the American Heart Association (ACC/AHA) last issued evidence-based guidelines in 2013, and since then, new drugs and devices have been developed. This review presents an evidence-based approach to current heart failure management.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Aminobutyrates / therapeutic use
  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Biphenyl Compounds
  • Cardiac Resynchronization Therapy Devices
  • Defibrillators, Implantable
  • Digoxin / therapeutic use
  • Diuretics / therapeutic use
  • Drug Combinations
  • Evidence-Based Medicine
  • Exercise
  • Heart Failure / physiopathology
  • Heart Failure / therapy*
  • Heart-Assist Devices
  • Humans
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Natriuretic Peptide, Brain / blood
  • Peptide Fragments / blood
  • Practice Guidelines as Topic
  • Systole
  • Tetrazoles / therapeutic use
  • Valsartan

Substances

  • Adrenergic beta-Antagonists
  • Aminobutyrates
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Biphenyl Compounds
  • Diuretics
  • Drug Combinations
  • Mineralocorticoid Receptor Antagonists
  • Peptide Fragments
  • Tetrazoles
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain
  • Digoxin
  • Valsartan
  • sacubitril and valsartan sodium hydrate drug combination